An independent, single-center, head-to-head trial showed that SYNVISC® provides superior pain relief versus Hyalgan®.1 In a meta-analysis of the efficacy of viscosupplements, SYNVISC delivered unsurpassed pain relief.2
SYNVISC provided superior pain relief for osteoarthritis1
Study detail:
- Prospective, observer-blinded, randomized, single-center, active-controlled trial of 392 patients with osteoarthritis knee pain
- 3 injections of SYNVISC vs. 5 injections of Hyalgan
- 26-week follow-up shown
- Independently funded
Data shown for follow-up visits at six weeks, three months and six months. Mean age of patients was 67.2 years. Most had radiographically confirmed Kellgren-Lawrence grade III OA at baseline (SYNVISC 61%; Hyalgan 59%). Pain was measured on a 10-cm visual analog scale (VAS).
SYNVISC provided unsurpassed osteoarthritis pain relief2
From a meta-analysis evaluating the therapeutic efficacy and safety of viscosupplements on knee OA. Relevant databases were searched for blinded, randomized, well-controlled trials comparing a viscosupplement product to placebo. Twenty trials, involving 1647 randomly assigned knees, were included in the meta-analysis. In addition to trials involving SYNVISC, the meta-analysis included trials of the non-cross-linked viscosupplements Hyalgan® (sodium hyaluronate), Supartz® (sodium hyaluronate), Orthovisc® (high molecular weight hyaluronan) and Euflexxa™ (1% sodium hyaluronate). Data shown are from a secondary analysis comparing two trials of SYNVISC vs. placebo with 15 trials of non-cross-linked viscosupplements vs. placebo.2
![[]](/sites/SynviscHCP/Resources/img/home/icon_green_square_off.gif){kind=icon}
Terms and Conditions of Use Privacy Policy Site Map